Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2022 Nov 24;22(1):883.
doi: 10.1186/s12879-022-07871-9.

Publisher Correction: Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study

Vincenzo Scaglione  1 , Salvatore Rotundo  1 , Nadia Marascio  2 , Carmela De Marco  3 , Rosaria Lionello  1 , Claudia Veneziano  3 , Lavinia Berardelli  1 , Angela Quirino  2 , Vincenzo Olivadese  1 , Francesca Serapide  1 , Bruno Tassone  1 , Helen Linda Morrone  1 , Chiara Davoli  1 , Valentina La Gamba  1 , Andrea Bruni  4 , Bruno Mario Cesana  5 , Giovanni Matera  2 , Alessandro Russo  1 , Francesco Saverio Costanzo  6 , Giuseppe Viglietto  3 , Enrico Maria Trecarichi  1 , Carlo Torti  7 ; IDTM U. M. G. COVID-19 Group
Collaborators, Affiliations
Published Erratum

Publisher Correction: Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study

Vincenzo Scaglione et al. BMC Infect Dis. .
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow chart of drugs prescription choices according to risk of progression of COVID-19. *Presence of at least one of the following factors: age > 65 years, BMI ≥ 30, patients chronically subjected to peritoneal dialysis or haemodialysis, uncontrolled diabetes mellitus or with chronic complications, primitive or secondary immunodeficiency (particularly concerning patients being treated with immunosuppressive drugs or less than 6 months from suspension of treatment), cardiocerebrovascular disease (including arterial hypertension with organ damage), COPD and/or other chronic respiratory diseases (lung fibrosis or patient needing O2-therapy for reasons different from SARS-CoV-2 infection), active oncological or oncohematological disease, chronic hepatopathy, hemoglobinopathies, neurodegenerative disorders. 1Patients affected by haematological malignancies/autoimmune diseases or treated with immunosuppressive drugs or transplant receivers; 2First choice in patients with eGFR > 30 ml/min and no major drug interactions; 3Useful in patients with eGFR > 30 ml/min if major drug interactions contraindicate nirmatrelvir/ritonavir or in patients with dysphagia; 4For use in patients with severe renal insufficiency and/or partially immunised (i.e., previous SARS-CoV-2 infection, vaccination course incomplete or completed more than 6 months before); 5mAbs therapy was chosen considering local epidemiology of variants of concern
See this image and copyright information in PMC

Erratum for

References

    1. Scaglione V, Rotundo S, Marascio N, De Marco C, Lionello R, Veneziano C, Berardelli L, Quirino A, Olivadese V, Serapide F, Tassone B, Morrone HL, Davoli C, La Gamba V, Bruni A, Cesana BM, Matera G, Russo A, Costanzo FS, Viglietto G, Trecarichi EM, Torti C. Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study. BMC Infect Dis. 2022;22:793. doi: 10.1186/s12879-022-07774-9. - DOI - PMC - PubMed

Publication types

LinkOut - more resources